Showing 1861-1870 of 3223 results for "".
- Cedars-Sinai Analysis Evaluates How Retinal Changes Correspond to Cognitive Changes in Alzheimer’s Diseasehttps://modernod.com/news/new-insights-eye-damage-in-alzheimers-disease-patients/2481455/Cedars-Sinai investigators have produced an analysis evaluating how retinal changes correspond to brain and cognitive changes in Alzheimer’s disease patients. Investigators looked at retinal and brain tissue samples collected over 14 years from 86 human donors—the
- Aldeyra Therapeutics Announces Positive Topline Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-12-month-safety-clinical-trial-of-reproxalap-in-patients-with-dry-eye-disease/2481437/Aldeyra Therapeutics announced topline results from a 12-month, vehicle-controlled, multicenter, parallel-group safety clinical trial of reproxalap, an investigational new drug in dry eye disease patients. The primary endpoints of treatment-related serious adverse events in ocular safet
- Alcon Launches "Alcon Experience Academy" App, Expanding On-Demand Learninghttps://modernod.com/news/alcon-launches-experience-academy-app-expanding-remote-on-demand-learning/2481422/Alcon announced the launch of the Alcon Experience Academy (AEA) app, which aims to help optimize eye care professionals’ (ECPs) digital learning experiences. The launch of the app brings AEA’s education and training resources to customers’ fingertips. The customizable
- Allegro Ophthalmics Provides Updates on Dry AMD Pipeline Candidateshttps://modernod.com/news/allegro-ophthalmics-provides-updates-on-dry-amd-pipeline-candidates/2481403/Allegro Ophthalmics announced the presentation of data supporting dry AMD pipeline candidates, including risuteganib (Luminate), at the Bascom Palmer Eye Institute's 20th annual
- FDA Accepts NDA for Aldeyra's Reproxalap for the Treatment of Dry Eye Diseasehttps://modernod.com/news/fda-accepts-nda-for-aldeyras-reproxalap-for-the-treatment-of-dry-eye-disease/2481392/Aldeyra Therapeutics announced that the FDA has accepted the new drug application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee A
- Nidek Launches Cube Alpha Ophthalmic Surgical Systemhttps://modernod.com/news/nidek-launches-cube-a-ophthalmic-surgical-system/2481390/Nidek has announced the launch of the Cube α ophthalmic surgical system, which is designed to incorporate new ultrasound technology to deliver more powerful and effective phacoemulsification. According to Nidek, the Cube α incorporates Gyro torsional technolog
- Alcon Canada Launches TOTAL Toric Lenses for Astigmatic Patientshttps://modernod.com/news/alcon-canada-launches-total-toric-lenses-for-astigmatic-patients/2481383/Alcon announced the Canadian launch of Total30 for Astigmatism and Dalies Total1 for Astigmatism, extending Alcon’s portfolio of reusable and daily disposable lenses for astigmatic patients. Estimates show that toric lenses is the fastest growing
- Alcon Champions Access to Eye Care with Opening of Children’s Vision Center in Fort Worth, Texashttps://modernod.com/news/alcon-champions-access-to-eye-care-with-opening-of-childrens-vision-center-in-fort-worth-texas/2481337/Alcon announced the grand opening of the Alcon Children’s Vision Center. Located at 8376 Mojave Trail in Fort Worth, Texas, the center is a first-of-its-kind partnership between the Alcon Foundation and the Fort Worth Independent School District (FWISD). The center offers comprehensive
- FCI Ophthalmics Announces Availability of EzyPor Polyethylene Orbital Implanthttps://modernod.com/news/fci-ophthalmics-announces-availability-of-ezypor-polyethylene-orbital-implant/2481336/FCI Ophthalmics announced the launch of EzyPor in the United States. EzyPor is a high density polyethylene orbital implant with a patented suturing platform, indicated for enucleation, evisceration, and secondary implantation. Ezyor is designed to have a smooth
- Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officerhttps://modernod.com/news/alimera-sciences-appoints-industry-veteran-russell-l-skibsted-as-chief-financial-officer/2481331/Alimera Sciences announced the appointment of Russell L. Skibsted as Senior Vice President and Chief Financial Officer (CFO), effective January 9, 2023. “We are extremely excited to have someone of Russell’s caliber join us here at Alimera,” Rick Eiswirth, P